ClinicalTrials.Veeva

Menu
I

Infectious Disease Specialists of Atlanta | Decatur, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
TAF
Tenofovir Disoproxil Fumarate
Tenofovir Alafenamide
Ritonavir
Islatravir
TDF
Rilpivirine
Efavirenz
Bictegravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 39 total trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab
Locations recently updated

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Placebo for Budigalimab
Drug: Budigalimab

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: LEN
Locations recently updated

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Bristol-Myers Squibb (BMS) logo
ViiV Healthcare logo
AbbVie logo
GlaxoSmithKline (GSK) logo
Roche logo
Summit Therapeutics logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems